Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–19
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol
Written informed consent obtained from the subject prior to performing any study specific procedure
A male or female subject aged 18 to 19 years at the time of enrolment (up to but excluding the 20th birthday)
Documented administration of 2 doses of Havrix® Junior in the second year of life
Healthy subjects as established by medical history and clinical examination before entering into the study
Female subjects of childbearing potential may be enrolled in the study, if the subject:
has practiced adequate contraception for 30 days prior to study vaccine administration, and has a negative pregnancy test on the day of vaccine administration, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the study vaccine administration
You may not be if
Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the dose of study vaccine (Day 29 to Day1), or planned use during the study period
Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe
Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting six months prior to the vaccine dose. For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed
Administration of long-acting immune-modifying drugs at any time during the study entry
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product
Administration of any hepatitis A vaccine dose, with the exception of the two doses of routine toddler vaccination for the subjects
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
Planned enrolment in the Israel Defense Forces within 30 days of study enrolment or activity that would prohibit the subject to return for Visit 2
Acute disease and/or fever at the time of enrolment Fever is defined as temperature ≥38.0°C / 100.4°F. The preferred location for measuring temperature in this study will be the oral cavity Subjects with a minor illness without fever may be enrolled at the discretion of the investigator
Pregnant or lactating female
Female planning to become pregnant or planning to discontinue contraceptive precautions